RASi therapy had a clinical benefit in both slowly progressing cancers, such as prostate cancer, and highly aggressive tumor types, such as glioblastoma and pancreatic cancer (tables S2 and S3). Here, MMP19 is linked to familial pancreatic carcinoma.